Marcel M Verbeek Selected Research

Levodopa (L Dopa)

5/2022	Mechanisms of peripheral levodopa resistance in Parkinson's disease.
3/2021	Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase.
12/2013	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
6/2010	Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis.
8/2008	Two Greek siblings with sepiapterin reductase deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcel M Verbeek Research Topics

Disease

89	Alzheimer Disease (Alzheimer's Disease) 05/2024 - 07/2002
39	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 05/2024 - 10/2002
27	Dementia (Dementias) 04/2022 - 10/2004
21	Cognitive Dysfunction 05/2024 - 07/2013
20	Parkinson Disease (Parkinson's Disease) 05/2022 - 05/2004
14	Amyloid Plaque 04/2024 - 07/2002
12	Familial Cerebral Amyloid Angiopathy 07/2023 - 10/2002
10	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 10/2009
8	Frontotemporal Dementia (Semantic Dementia) 01/2017 - 01/2009
7	Parkinsonian Disorders (Parkinsonism) 11/2021 - 07/2008
6	Movement Disorders (Movement Disorder) 05/2022 - 08/2008
6	Multiple System Atrophy 11/2021 - 05/2004
6	Inflammation (Inflammations) 01/2020 - 04/2006
6	Synucleinopathies 01/2017 - 10/2004
5	Glut1 Deficiency Syndrome 01/2023 - 09/2013
5	Disease Progression 01/2023 - 01/2017
4	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 07/2014 - 07/2006
3	Intellectual Disability (Idiocy) 05/2022 - 03/2010
3	Multiple Sclerosis 01/2020 - 11/2012
3	Neuromyelitis Optica (Devic's Disease) 01/2020 - 06/2012
3	Atrophy 01/2018 - 01/2014
3	Inclusion Body Myositis 04/2016 - 09/2009
3	Lewy Body Disease (Lewy Body Dementia) 09/2015 - 07/2013
3	Nervous System Diseases (Neurological Disorders) 12/2013 - 05/2007
2	Gliosis 04/2024 - 04/2022
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2021 - 04/2011
2	Orthostatic Hypotension (Postural Hypotension) 01/2021 - 01/2018
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021 - 10/2009
2	autosomal recessive Segawa syndrome 01/2021 - 06/2010
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2017 - 01/2014
2	Cerebral Small Vessel Diseases 01/2017 - 01/2017
2	Dermatomyositis (Dermatopolymyositis) 04/2016 - 03/2013
2	Brain Diseases (Brain Disorder) 01/2015 - 01/2010
2	Muscle Hypotonia (Hypotonia) 04/2014 - 01/2012
2	Dystonia (Limb Dystonia) 04/2014 - 01/2012
2	Coma (Comas) 10/2013 - 02/2012
2	Hypertension (High Blood Pressure) 12/2012 - 01/2008
2	Neoplasms (Cancer) 01/2008 - 09/2006
2	Neoplasm Metastasis (Metastasis) 09/2006 - 09/2005
1	App-Related Cerebroarterial Amyloidosis 03/2024
1	succinic semialdehyde dehydrogenase deficiency 07/2023
1	Cerebral Hemorrhage 01/2022
1	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 01/2022

Drug/Important Bio-Agent (IBA)

77	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2007
46	Amyloid (Amyloid Fibrils)IBA 02/2024 - 10/2002
28	Amyloid beta-PeptidesIBA 05/2024 - 07/2002
26	Proteins (Proteins, Gene)FDA Link 01/2024 - 09/2005
11	Peptides (Polypeptides)IBA 02/2024 - 09/2005
8	SynucleinsIBA 04/2021 - 01/2010
6	EnzymesIBA 03/2021 - 12/2002
6	tau Proteins (tau Protein)IBA 10/2016 - 05/2007
5	Levodopa (L Dopa)FDA LinkGeneric 05/2022 - 08/2008
5	Apolipoproteins E (ApoE)IBA 01/2022 - 04/2005
5	Glucose (Dextrose)FDA LinkGeneric 12/2013 - 03/2010
5	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 04/2010 - 07/2002
4	Glial Fibrillary Acidic ProteinIBA 04/2024 - 01/2010
4	ApolipoproteinsIBA 01/2018 - 04/2005
4	alpha-SynucleinIBA 09/2015 - 10/2004
3	CytokinesIBA 01/2023 - 11/2002
3	Complement System Proteins (Complement)IBA 01/2023 - 01/2010
3	Protein Isoforms (Isoforms)IBA 01/2018 - 01/2015
3	MicroRNAs (MicroRNA)IBA 12/2017 - 01/2014
3	AutoantibodiesIBA 04/2016 - 03/2013
3	ImmunosorbentsIBA 09/2015 - 12/2002
3	MethoxyhydroxyphenylglycolIBA 07/2014 - 01/2011
3	OrexinsIBA 01/2013 - 10/2009
3	Small Heat-Shock ProteinsIBA 02/2009 - 02/2006
2	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2024 - 01/2010
2	gamma-Aminobutyric Acid (GABA)IBA 07/2023 - 01/2021
2	Codon (Codons)IBA 01/2022 - 01/2012
2	Glucose-6-Phosphate Isomerase (Phosphoglucose Isomerase)IBA 11/2021 - 01/2021
2	Nerve Growth Factors (Neurotrophins)IBA 11/2021 - 01/2021
2	Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA 01/2020 - 03/2015
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018 - 12/2013
2	AntibodiesIBA 01/2018 - 03/2013
2	EpitopesIBA 04/2016 - 10/2002
2	5'-Nucleotidase (5' Nucleotidase)IBA 04/2016 - 03/2013
2	CatecholaminesIBA 08/2015 - 06/2010
2	AntigensIBA 09/2014 - 11/2012
2	Lactic Acid (Lactate)FDA LinkGeneric 11/2013 - 01/2012
2	Phosphopyruvate Hydratase (Enolase)IBA 10/2013 - 02/2012
2	Homovanillic AcidIBA 06/2010 - 10/2007
2	GlycosaminoglycansIBA 04/2010 - 10/2004
2	ChemokinesIBA 09/2006 - 04/2006
2	Amyloid beta-Protein Precursor (Amyloid Protein Precursor)IBA 02/2006 - 08/2005
1	Claudin-5IBA 05/2024
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2023
1	Type II Tumor Necrosis Factor ReceptorsIBA 01/2023
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2023
1	Matrix Metalloproteinase InhibitorsIBA 01/2023
1	Matrix Metalloproteinases (MMPs)IBA 01/2023
1	Aromatic-L-Amino-Acid DecarboxylasesIBA 05/2022
1	VS 215IBA 04/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022

Therapy/Procedure

4	Therapeutics 01/2023 - 10/2002
2	Immunotherapy 01/2022 - 11/2017
2	Ketogenic Diet 09/2013 - 03/2010